株探米国株
エドガーで原本を確認する
6-K 1 f6k_061726.htm FORM 6-K


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2026

 

(Commission File No. 001-43107)

 

SATELLOS BIOSCIENCE INC.

(Translation of registrant’s name into English)

 

15 Allstate Parkway, Suite 600

Markham, Ontario, Canada, L3R 5B4

(Address of registrant’s principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☐               Form 40-F ☒ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 


DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

 

Exhibit Description
   
99.1 Report of Voting Results

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


SIGNATURES

 

 

  Satellos Bioscience Inc.
     
  By: /s/ Elizabeth Williams, CPA, CA
  Name: Elizabeth Williams, CPA, CA
  Title: Chief Financial Officer

 

Date: June 17, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EX-99.1 2 exh_991.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Report of Voting Results

Satellos Bioscience Inc.

 

In accordance with Section 11.3 of National Instrument 51-102, the following briefly describes the matters voted upon and the outcome of the votes at the annual meeting of shareholders of Satellos Bioscience Inc. (the “Company”) held virtually on June 17, 2026 (the “Meeting”). Full details of the matters are set out in the Company’s management information circular dated May 14, 2026, which is available on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov).

 

1. By resolution passed by way of ballot, each of the nominees for election as directors was elected to hold office until the next annual meeting of shareholders or until such director resigns or a successor is elected or appointed. Votes at the Meeting were as follows:

 

Director Votes For % For Votes Against % Against
Frank Gleeson 9,473,905 99.94 5,348 0.06
Franklin M. Berger 9,478,576 99.99 677 0.01
Brian Bloom 9,476,755 99.97 2,498 0.03
Stephanie Brown 8,741,404 92.22 737,849 7.78
Selwyn Ho 9,473,538 99.94 5,715 0.06
Iris Loew-Friedrich 7,939,800 83.76 1,539,453 16.24
Geoff Mackay 9,449,959 99.69 29,294 0.31
Adam Mostafa 9,450,311 99.69 28,942 0.31
Mark Nawacki 9,477,041 99.98 2,212 0.02

 

2. By resolution passed by way of ballot, PricewaterhouseCoopers LLP was appointed as auditor of the Company to hold office until the next annual meeting or until its successor is appointed, and the directors were authorized to fix its remuneration. 98.69% of the votes represented in person or by proxy at the Meeting were in favour of the appointment and 1.31% were withheld from voting.

 

In total, approximately 55.33% of the issued and outstanding shares were represented in person or by proxy at the Meeting.

 

Yours very truly,

 

/s/ Liz Williams

Chief Financial Officer and Corporate Secretary